June 13, 2014
The U.S. government on Thursday weighed in on Celgene Corp.’s bid to nix a whistleblower’s False Claims Act suit in California federal court over alleged off-label drug promotions and kickbacks to doctors, arguing the drug company prematurely moved for dismissal and relied on faulty theories about what constitutes a false claim.
April 29, 2014
Celgene Corp. on Friday urged a California federal judge to ax a whistleblower's False Claims Act complaint over alleged kickbacks to doctors, saying the lawsuit doesn't claim that off-label uses without medical support were promoted and therefore doesn't describe possible fraud.
February 06, 2014
A former sales representative for Celgene Corp. is accusing the drugmaker of paying kickbacks to doctors for prescribing its cancer drugs Thalomid and Revlimid, and of marketing them for off-label uses that government programs including Medicare ended up paying for, according to court documents unsealed Thursday.